Statistics & Data Corporation   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Tempe AZ United States (2006)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2013
NCT03886779
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Statistics & Data Corporation

Active Ingredients

Drugs in Phase 4 Trials (2)

bromfenac (xibrom) (1 trial)

nepafenac (nevanac) (1 trial)

Drugs in Phase 3 Trials (1)

ot-101 (1 trial)

Drugs in Phase 2 Trials (1)

dupilumab (dupixent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 4)

Inflammation (Phase 4)

Keratoconjunctivitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4